Abstract 4640: Benefit of combining DLL3 targeted alpha therapy with standard of care in preclinical small cell lung cancer models
Year: 2026
Type: conference-abstract
Source: Cancer Research
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148782990
Cites:
Cited by:
Related to: